Fundraising FoxArtis Ventures — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Founder)inScott Boyken(Founder)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in
Co-investorsRA CapitalAbstract VenturesATEL VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, LlcGaingels+9 more
__Twitter.png)
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)inJoshua Yang(Founder)
BoardCraig Asher(Director)inJimmy Yun(Director)in
Co-investorsBlack FlagCivilization Ventures Management, LlcFoundersX VenturesGaingelsHarpoon VenturesIn-Q-Tel+11 more
Siren Biotechnology develops next-generation AAV (adeno-associated virus) platforms for gene therapy applications, including gene repair, gene transfer, and gene editing.
BiotechDigital HealthMedical DevicesSan Francisco, US
Dr. Nicole Paulk(CEO, Founder, and President)inLauren Kelly(Founder)inSharon Tetlow(Director)Brad Allen(Director)
Co-investorsAvilaCarnrite VenturesCivilization Ventures Management, LlcGaingelsHAWKTAILNZVC+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.